CL2004000647A1 - Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am - Google Patents

Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am

Info

Publication number
CL2004000647A1
CL2004000647A1 CL200400647A CL2004000647A CL2004000647A1 CL 2004000647 A1 CL2004000647 A1 CL 2004000647A1 CL 200400647 A CL200400647 A CL 200400647A CL 2004000647 A CL2004000647 A CL 2004000647A CL 2004000647 A1 CL2004000647 A1 CL 2004000647A1
Authority
CL
Chile
Prior art keywords
inhibitors
amiloid
beta
angiopatia
heterocicles
Prior art date
Application number
CL200400647A
Other languages
English (en)
Spanish (es)
Inventor
Anthony Frank Resnick Ly Kreft
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CL2004000647A1 publication Critical patent/CL2004000647A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL200400647A 2003-03-31 2004-03-26 Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am CL2004000647A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45922803P 2003-03-31 2003-03-31

Publications (1)

Publication Number Publication Date
CL2004000647A1 true CL2004000647A1 (es) 2005-02-04

Family

ID=33299665

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400647A CL2004000647A1 (es) 2003-03-31 2004-03-26 Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am

Country Status (22)

Country Link
US (3) US7300951B2 (US07858658-20101228-C00038.png)
EP (1) EP1608638A1 (US07858658-20101228-C00038.png)
JP (1) JP2006522126A (US07858658-20101228-C00038.png)
KR (1) KR20060002908A (US07858658-20101228-C00038.png)
CN (2) CN1780829B (US07858658-20101228-C00038.png)
AR (1) AR043940A1 (US07858658-20101228-C00038.png)
AU (1) AU2004230844B2 (US07858658-20101228-C00038.png)
BR (1) BRPI0408962A (US07858658-20101228-C00038.png)
CA (1) CA2517155A1 (US07858658-20101228-C00038.png)
CL (1) CL2004000647A1 (US07858658-20101228-C00038.png)
CO (1) CO5640049A2 (US07858658-20101228-C00038.png)
CR (1) CR7951A (US07858658-20101228-C00038.png)
EC (1) ECSP056128A (US07858658-20101228-C00038.png)
MX (1) MXPA05010368A (US07858658-20101228-C00038.png)
NO (1) NO20054263L (US07858658-20101228-C00038.png)
NZ (1) NZ542468A (US07858658-20101228-C00038.png)
RU (1) RU2342374C2 (US07858658-20101228-C00038.png)
SG (1) SG167669A1 (US07858658-20101228-C00038.png)
TW (1) TWI336698B (US07858658-20101228-C00038.png)
UA (1) UA82093C2 (US07858658-20101228-C00038.png)
WO (1) WO2004092155A1 (US07858658-20101228-C00038.png)
ZA (1) ZA200507896B (US07858658-20101228-C00038.png)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2436526C (en) * 2000-12-13 2010-10-19 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production
RS51155B (sr) * 2001-12-20 2010-10-31 Bristol-Myers Squibb Company DERIVATI α -(N-SULFONAMIDO)ACETAMIDA KAO INHIBITORI β -AMILOIDA
EP1549306A4 (en) * 2002-06-11 2007-06-06 Wyeth Corp PHENYLSULFONAMIDE SUBSTITUTED INHIBITORS OF BETA-AMYLOID PRODUCTION
NZ542468A (en) * 2003-03-31 2009-01-31 Wyeth Corp Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
CN1910158A (zh) * 2004-01-16 2007-02-07 惠氏公司 含有氮杂环的β淀粉样蛋白生成的杂环磺酰胺抑制剂
BRPI0707741A2 (pt) * 2006-02-17 2011-05-10 Wyeth Corp mÉtodos para preparar um amino Álcool, ou sal do mesmo, e um Álcool substituÍdo por sulfonamida
AR059517A1 (es) 2006-02-17 2008-04-09 Wyeth Corp N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
JP2009534385A (ja) 2006-04-21 2009-09-24 ワイス キラル的に純粋なアミノアルコール中間体、それらの誘導体の製造、及びそれらの使用
US7550629B2 (en) * 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
WO2008063849A2 (en) * 2006-11-03 2008-05-29 Northwestern University Multiple sclerosis therapy
EP2193117A1 (en) * 2007-07-16 2010-06-09 Wyeth a Corporation of the State of Delaware Inhibitors of beta amyloid production
CL2008002058A1 (es) * 2007-07-16 2008-11-14 Wyeth Corp Metodo para la preparacion de trifluoralquil-fenil-sulfonamidas y de sulfonamidas heterociclicas usando n-trifluoroacteilmorfolina; su metodo de preparacion y su uso.
TW200914409A (en) * 2007-07-16 2009-04-01 Wyeth Corp Processes and intermediates for the preparation of heterocyclic sulfonamide compounds
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
TW200934482A (en) * 2008-01-11 2009-08-16 Wyeth Corp Compositions containing o-sulfate and o-phosphate containing aryl sulfonamide derivatives useful as β -amyloid inhibitors
WO2009137657A1 (en) * 2008-05-08 2009-11-12 Bristol-Myers Squibb Company 2-aryl glycinamide derivatives
EP2334620B1 (en) * 2008-09-05 2018-09-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Process for enantioseparation of chiral systems with compound formation using two subsequent crystallization steps
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) * 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US20110071199A1 (en) * 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
WO2011084503A1 (en) * 2009-12-16 2011-07-14 North Carolina Central University Phenoxy thiophene sulfonamides and their use in the treatment of neurodegenerative diseases
US9223217B2 (en) * 2010-02-19 2015-12-29 International Business Machines Corporation Sulfonamide-containing topcoat and photoresist additive compositions and methods of use
US9223209B2 (en) * 2010-02-19 2015-12-29 International Business Machines Corporation Sulfonamide-containing photoresist compositions and methods of use
WO2011112858A1 (en) * 2010-03-10 2011-09-15 North Carolina Central University Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
JP2015527398A (ja) 2012-09-07 2015-09-17 マサチューセッツ アイ アンド イヤー インファーマリー 聴覚喪失治療
US20160067306A1 (en) 2013-04-19 2016-03-10 National University Corporation Hokkaido University Treatment agent for cognitive impairment induced by amyloid beta-protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
WO2016069906A1 (en) 2014-10-29 2016-05-06 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
JP6840774B2 (ja) 2016-05-16 2021-03-10 ザ ジェネラル ホスピタル コーポレイション 肺上皮エンジニアリングにおけるヒト気道幹細胞
WO2019148067A1 (en) 2018-01-26 2019-08-01 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
EP4299062A1 (en) 2022-06-30 2024-01-03 Vilnius University Inhibition of protein amyloid aggregation using fluorinated benzenesulfonamides

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
KR920019763A (ko) 1991-04-26 1992-11-19 모리다 가즈라 아졸 화합물, 그의 제조방법 및 용도
GB9110722D0 (en) 1991-05-17 1991-07-10 Fujisawa Pharmaceutical Co Amine derivatives
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6376523B1 (en) * 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
CZ184194A3 (en) 1993-08-09 1995-03-15 Lilly Co Eli Aspartylprotease inhibitor and method of identifying thereof
US5519040A (en) 1994-04-29 1996-05-21 Allergan Substituted thiazole sulfonamides as antiglaucoma agents
US5624937A (en) * 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
AU714324B2 (en) * 1995-11-28 2000-01-06 Cephalon, Inc. D-amino acid derived inhibitors of cysteine and serine proteases
AU740263C (en) 1996-07-22 2002-05-16 Monsanto Company Thiol sulfonamide metalloprotease inhibitors
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
US5985930A (en) 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
AU5354398A (en) 1996-11-22 1998-06-10 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions compri sing same, and methods for inhibiting beta-amyloid peptide release and/or it s synthesis by use of such compounds
DE19650196A1 (de) * 1996-12-04 1998-06-10 Bayer Ag Thienylsulfonylamino(thio)carbonylverbindungen
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US5981168A (en) * 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
AU773273B2 (en) 1999-02-26 2004-05-20 Bristol-Myers Squibb Company Novel sulfonamide compounds and uses thereof
PL351374A1 (en) 1999-04-19 2003-04-07 Shionogi & Co Sulfonamide derivatives having oxadiazole rings
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1218377A1 (en) 1999-10-08 2002-07-03 Bristol-Myers Squibb Pharma Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION
US7365196B2 (en) 2000-03-20 2008-04-29 Merck Sharp & Dohme Ltd. Sulphonamido-substituted bridged bicycloalkyl derivatives
US6657070B2 (en) * 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
CA2436526C (en) * 2000-12-13 2010-10-19 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production
IL162059A0 (en) * 2001-12-11 2005-11-20 Wyeth Corp Process for the synthesis of -amino- chirally purealcohols
WO2003050062A2 (en) 2001-12-11 2003-06-19 Wyeth PRODUCTION OF CHIRALLY PURE α-AMINO ACIDS ADN N-SULFONYL α-AMINO ACIDS
EP1549306A4 (en) * 2002-06-11 2007-06-06 Wyeth Corp PHENYLSULFONAMIDE SUBSTITUTED INHIBITORS OF BETA-AMYLOID PRODUCTION
NZ542468A (en) 2003-03-31 2009-01-31 Wyeth Corp Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
CN1910158A (zh) 2004-01-16 2007-02-07 惠氏公司 含有氮杂环的β淀粉样蛋白生成的杂环磺酰胺抑制剂
BRPI0707741A2 (pt) 2006-02-17 2011-05-10 Wyeth Corp mÉtodos para preparar um amino Álcool, ou sal do mesmo, e um Álcool substituÍdo por sulfonamida
AR059517A1 (es) 2006-02-17 2008-04-09 Wyeth Corp N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo
US7550629B2 (en) 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
JP2009534385A (ja) 2006-04-21 2009-09-24 ワイス キラル的に純粋なアミノアルコール中間体、それらの誘導体の製造、及びそれらの使用
US7476762B2 (en) 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
CL2008002058A1 (es) 2007-07-16 2008-11-14 Wyeth Corp Metodo para la preparacion de trifluoralquil-fenil-sulfonamidas y de sulfonamidas heterociclicas usando n-trifluoroacteilmorfolina; su metodo de preparacion y su uso.
EP2193117A1 (en) 2007-07-16 2010-06-09 Wyeth a Corporation of the State of Delaware Inhibitors of beta amyloid production
TW200914409A (en) 2007-07-16 2009-04-01 Wyeth Corp Processes and intermediates for the preparation of heterocyclic sulfonamide compounds

Also Published As

Publication number Publication date
US20040198778A1 (en) 2004-10-07
ZA200507896B (en) 2007-03-28
JP2006522126A (ja) 2006-09-28
CN1780829B (zh) 2010-12-29
TW200504047A (en) 2005-02-01
US20070254929A1 (en) 2007-11-01
US7300951B2 (en) 2007-11-27
UA82093C2 (uk) 2008-03-11
CN101274926A (zh) 2008-10-01
EP1608638A1 (en) 2005-12-28
RU2342374C2 (ru) 2008-12-27
NO20054263L (no) 2005-12-14
AR043940A1 (es) 2005-08-17
NZ542468A (en) 2009-01-31
ECSP056128A (es) 2006-03-01
RU2005133434A (ru) 2006-07-10
US20090227667A1 (en) 2009-09-10
CN1780829A (zh) 2006-05-31
AU2004230844A1 (en) 2004-10-28
NO20054263D0 (no) 2005-09-15
MXPA05010368A (es) 2005-11-17
KR20060002908A (ko) 2006-01-09
US7547725B2 (en) 2009-06-16
CA2517155A1 (en) 2004-10-28
BRPI0408962A (pt) 2006-04-04
CO5640049A2 (es) 2006-05-31
TWI336698B (en) 2011-02-01
SG167669A1 (en) 2011-01-28
AU2004230844B2 (en) 2010-12-09
CR7951A (es) 2008-10-29
US7858658B2 (en) 2010-12-28
WO2004092155A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
CL2004000647A1 (es) Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
PA8583401A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
DOP2006000084A (es) Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos compuestos, metodos de preparacion y usos de los mismos
UY28215A1 (es) Quinazolinas utiles como moduladores de canales iónicos
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
PA8719401A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
GT200600199A (es) Diarilsulfonas sulfonamidas y su uso
ECSP066763A (es) Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
PA8604201A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA201070424A1 (ru) Хиназолиндионовые производные, их получение и их применения в терапии
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
SV2004001555A (es) Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos
PA8603001A1 (es) Compuestos utiles para el tratamiento de enfermedades